DrugPatentWatch

DrugPatentWatch Archives

You are currently viewing the 2001 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ALDARA

Summary for Tradename: ALDARA

Patents:2
Applicants:1
NDAs:1
Suppliers: see list3
drug
patent expirations by year for
 ALDARA

Pharmacology for Tradename: ALDARA

Clinical Trials for: ALDARA

Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
Status: Completed Condition: Port Wine Stain

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
Status: Completed Condition: Actinic Keratoses

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Status: Suspended Condition: Melanoma

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses
Status: Completed Condition: Actinic Keratoses

Bioequivalence Study of Two Imiquimod Cream 5%
Status: Completed Condition: Actinic Keratosis

Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses
Status: Recruiting Condition: Actinic Keratosis

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
Status: Completed Condition: Actinic Keratosis

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream
Status: Completed Condition: Actinic Keratosis

Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Completed Condition: Actinic Keratosis

Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
Status: Completed Condition: Superficial Basal Cell Carcinoma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
3m
ALDARA
imiquimod
Cream; Topical020723FEB 27, 1997RXYes<disabled><disabled>
3m
ALDARA
imiquimod
Cream; Topical020723FEB 27, 1997RXYes4,689,338<disabled><disabled>
3m
ALDARA
imiquimod
Cream; Topical020723FEB 27, 1997RXYes5,238,944<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ALDARA

Drugname Dosage Strength RLD Submissiondate
imiquimodCream5%Aldara10/17/2006

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc